Open AccessAbstract 3399: Preclinical evaluation of eFT226, a potent and selective eIF4A inhibitor with anti-tumor activity in FGFR1,2 and HER2 driven cancers
Author(s) -
P. Thompson,
Nathan P. Young,
Adina Gerson-Gurwitz,
Boreth Eam,
Vikas Goel,
Craig R. Stumpf,
Joan Chen,
Gregory S. Parker,
Sarah Fish,
Maria Barrera,
Eric Sung,
Jocelyn Staunton,
Gary G. Chiang,
Kevin R. Webster
Publication year - 2020
Publication title -
cancer research
Language(s) - English
Resource type - Conference proceedings
SCImago Journal Rank - 1.055
H-Index - 84
eISSN - 1538-7445
pISSN - 0008-5472
DOI - 10.1158/1538-7445.am2020-3399
Subject(s) - eif4e , eif4g , eif4a , biology , internal ribosome entry site , pi3k/akt/mtor pathway , eukaryotic translation , cancer research , translational efficiency , untranslated region , translation (biology) , five prime untranslated region , oncogene , initiation factor , microbiology and biotechnology , messenger rna , signal transduction , cell cycle , cancer , genetics , gene